The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Bio-Reference Laboratories's revenues will grow 15.9% and EPS will increase 24.3%.
The average estimate for revenue is $175.3 million. On the bottom line, the average EPS estimate is $0.46.
Last quarter, Bio-Reference Laboratories notched revenue of $172.3 million. GAAP reported sales were 16% higher than the prior-year quarter's $148.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.45. GAAP EPS of $0.45 for Q3 were 25% higher than the prior-year quarter's $0.36 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 51.9%, 40 basis points better than the prior-year quarter. Operating margin was 13.2%, 80 basis points better than the prior-year quarter. Net margin was 7.3%, 50 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $660.9 million. The average EPS estimate is $1.51.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 320 members out of 338 rating the stock outperform, and 18 members rating it underperform. Among 100 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 97 give Bio-Reference Laboratories a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bio-Reference Laboratories is buy, with an average price target of $28.40.
Is Bio-Reference Laboratories the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Bio-Reference Laboratories to My Watchlist.